Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MRTX1719 + Radiotherapy + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MRTX1719 | MRTX-1719|MRTX 1719|BMS 986504|BMS986504|BMS-986504|BMS986504|Navlimetostat | PRMT5 Inhibitor 21 | MRTX1719 inhibits the PRMT5-MTA complex, which potentially results in reduced tumor growth (PMID: 35041419). | |
| Radiotherapy | ||||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07492680 | Phase II | Nab-paclitaxel Carboplatin MRTX1719 Daraxonrasib + Gemcitabine + MRTX1719 + Nab-paclitaxel Daraxonrasib + MRTX1719 Pemetrexed Disodium MRTX1719 + Radiotherapy + Temozolomide BNT327 + MRTX1719 Paclitaxel MRTX1719 + Nivolumab and relatlimab-rmbw | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | Not yet recruiting | USA | NOR | ITA | IRL | FRA | ESP | DEU | CAN | BEL | 4 |